GO:0071757 hexameric IgM immunoglobulin complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071757 describes the hexameric IgM immunoglobulin complex, a circulating form of IgM composed of six IgM core units linked by a single J chain polypeptide.
• Hexameric IgM is one of the two major polymeric forms of IgM, the other being pentameric IgM; both are secreted by plasma cells and play key roles in humoral immunity.
• The hexameric assembly is stabilized by disulfide bonds and non-covalent interactions, and its N-glycosylation pattern differs from that of pentameric IgM.
• Hexameric IgM is a potent activator of the classical complement pathway, and its interaction with C1q is influenced by its oligomeric state.
• Recombinant hexameric IgM is being engineered for therapeutic applications, including immunocytokines and anti-PD-L1 antibodies.
• Studying hexameric IgM requires advanced methods such as site-specific N-glycosylation analysis, biolayer interferometry, and CRISPR-based genome editing to dissect assembly and function.
Description
The hexameric IgM immunoglobulin complex (GO:0071757) is a circulating form of immunoglobulin M (IgM) that consists of six IgM core units assembled with a single J chain polypeptide. IgM is the first antibody class produced during an immune response and is a potent activator of the complement system. While pentameric IgM is the more commonly studied polymeric form, hexameric IgM represents a significant fraction of serum IgM and exhibits distinct structural and functional properties. Understanding the biology of hexameric IgM is essential for researchers studying humoral immunity, antibody engineering, and complement-mediated diseases. Recent advances in recombinant expression and biophysical characterization have shed light on the assembly, glycosylation, and receptor interactions of hexameric IgM. This article provides a comprehensive overview of the hexameric IgM immunoglobulin complex, covering its definition, structure, biological functions, associated genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional studies.
hexameric IgM immunoglobulin complex At A Glance
| GO ID | GO:0071757 |
|---|---|
| GO term | hexameric IgM immunoglobulin complex |
| Ontology | cellular_component |
| Synonym | hexameric IgM antibody |
| Definition | A circulating form of IgM consisting of a hexamer of IgM core units with a single J chain polypeptide. |
| Major function | Complement activation, pathogen neutralization, and immune complex formation. |
| Cellular location | Extracellular space, secreted from plasma cells. |
| Assembly | Six IgM core units (each a tetramer of two heavy and two light chains) linked by a single J chain. |
| Post-translational modification | N-glycosylation at specific sites on the heavy chains, with distinct patterns compared to pentameric IgM. |
What Is GO:0071757?
According to the Gene Ontology (GO), the hexameric IgM immunoglobulin complex (GO:0071757) is defined as a circulating form of IgM consisting of a hexamer of IgM core units with a single J chain polypeptide. This complex is a cellular component located in the extracellular space, and it represents one of the two major polymeric forms of secreted IgM, the other being the pentameric form. The hexameric assembly is characterized by six IgM monomers (each composed of two heavy chains and two light chains) non-covalently associated and stabilized by disulfide bonds, with a single joining (J) chain that facilitates polymerization. The complex is produced by plasma cells and plays a critical role in the early immune response, particularly in complement activation and pathogen neutralization.
Why Is hexameric IgM immunoglobulin complex Important in Cell Biology?
The hexameric IgM immunoglobulin complex is important because it represents a key effector molecule of the humoral immune system. As a potent activator of the classical complement pathway, hexameric IgM can rapidly initiate complement-mediated lysis of pathogens and clearance of immune complexes. Its unique structure, with six antigen-binding sites per molecule, allows for high-avidity binding to multivalent antigens. Moreover, hexameric IgM is involved in the pathogenesis of autoimmune diseases and is being explored as a therapeutic scaffold for engineered antibodies. Understanding its biology is therefore crucial for immunology research, vaccine development, and the design of antibody-based therapeutics.
• Hexameric IgM is a major circulating form of IgM and plays a central role in the primary immune response.
• It is a potent activator of the classical complement pathway, leading to opsonization and lysis of pathogens.
• The hexameric structure provides six antigen-binding sites, enhancing avidity for multivalent antigens.
• Dysregulation of IgM complexes is associated with autoimmune diseases such as systemic lupus erythematosus.
• Recombinant hexameric IgM is being developed as a therapeutic platform for cancer immunotherapy.
• The J chain is essential for polymerization and secretion of hexameric IgM.
• N-glycosylation of hexameric IgM affects its stability, receptor binding, and effector functions.
• Hexameric IgM interacts with FcμR, a receptor involved in B cell development and immune regulation.
• Studying hexameric IgM assembly can reveal general principles of protein oligomerization and secretion.
• CRISPR-based genome editing enables precise manipulation of genes involved in hexameric IgM biosynthesis for functional studies.
What Happens During hexameric IgM immunoglobulin complex?
Biosynthesis and Assembly of IgM Subunits
In simple terms: The cell builds the individual pieces of IgM and then puts them together.
The biosynthesis of hexameric IgM begins in plasma cells with the synthesis of IgM heavy (μ) and light chains in the endoplasmic reticulum (ER). These chains assemble into monomeric IgM (H2L2) units, which then polymerize. The J chain is incorporated during polymerization and is critical for the formation of both pentameric and hexameric IgM. Studies using mutant subunits have elucidated the stepwise assembly and secretion of human IgM, showing that specific residues in the μ chain affect polymerization and secretion efficiency. The hexameric form arises from the assembly of six IgM monomers with one J chain, a process that is tightly regulated to ensure proper secretion.
Post-translational Modifications and Glycosylation
In simple terms: After assembly, sugar molecules are attached to IgM, which can affect its function.
Hexameric IgM undergoes extensive N-glycosylation at specific asparagine residues on the μ heavy chain. Site-specific N-glycosylation analysis of recombinant pentameric and hexameric human IgM has revealed distinct glycosylation patterns between the two forms, which may influence their stability, receptor binding, and effector functions. These post-translational modifications are important for the proper folding, assembly, and secretion of the complex.
Secretion and Circulation
In simple terms: Once assembled, IgM is released into the blood where it travels throughout the body.
After assembly in the ER and transit through the Golgi, hexameric IgM is secreted into the bloodstream. It circulates as a soluble complex and is found in serum and mucosal secretions. The secretion process is dependent on the J chain and proper disulfide bond formation. Circulating hexameric IgM can bind to antigens and form immune complexes, which are then cleared by phagocytes or activate complement.
Interaction with Complement and Receptors
In simple terms: IgM binds to other proteins in the blood to trigger immune responses.
Hexameric IgM is a potent activator of the classical complement pathway. It binds to C1q, the first component of the complement cascade, leading to complement activation. Biophysical characterization of recombinant IgM oligomers has shown that the hexameric form has distinct C1q-binding kinetics compared to pentameric IgM. Additionally, hexameric IgM interacts with FcμR, a receptor expressed on B cells and other immune cells, which mediates its internalization and modulates immune responses. These interactions are critical for the effector functions of hexameric IgM.
Receptor-mediated Clearance and Regulation
In simple terms: Special receptors on cells help remove IgM from circulation and regulate its levels.
The clearance of hexameric IgM from circulation is mediated by receptors such as FcμR. Studies have shown that FcμR specifically recognizes IgM and plays a role in its transport and degradation. The interaction between hexameric IgM and FcμR is influenced by the oligomeric state and glycosylation of IgM. This receptor-mediated clearance is important for maintaining homeostasis and preventing excessive immune activation.
Key Genes Involved in GO:0071757 hexameric IgM immunoglobulin complex
The following genes and proteins are critically involved in the biosynthesis, assembly, secretion, and function of the hexameric IgM immunoglobulin complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGHM | Encodes the μ heavy chain of IgM | Essential for IgM monomer formation; mutations affect assembly and secretion. |
| IGKC | Encodes the kappa light chain | Forms part of the IgM monomer; light chain composition affects antigen binding. |
| IGLC | Encodes the lambda light chain | Alternative light chain; influences IgM structure and function. |
| JCHAIN | Encodes the J chain polypeptide | Critical for polymerization of IgM into pentamers and hexamers. |
| C1QA | Encodes the A chain of C1q | Involved in complement activation by hexameric IgM. |
| C1QB | Encodes the B chain of C1q | Part of the C1q complex that binds IgM. |
| C1QC | Encodes the C chain of C1q | Part of the C1q complex that binds IgM. |
| FCAMR | Encodes FcμR, the IgM Fc receptor | Mediates IgM internalization and immune regulation. |
| CD5L | Encodes CD5 antigen-like protein | A canonical component of circulatory IgM, modulates its function. |
| PD-L1 (CD274) | Immune checkpoint ligand | Target of engineered hexameric IgM immunocytokines. |
| IL15 | Interleukin 15 | Fused to anti-PD-L1 IgM to enhance NK and T cell cytotoxicity. |
| C1R | Complement C1r subcomponent | Part of the C1 complex activated by IgM. |
| C1S | Complement C1s subcomponent | Part of the C1 complex activated by IgM. |
| C4 | Complement C4 | Downstream effector of complement activation by IgM. |
| C3 | Complement C3 | Central complement component activated by IgM. |
| B2M | Beta-2-microglobulin | Not directly involved in IgM assembly but used as a control in expression studies. |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Common loading control in IgM expression studies. |
| ACTB | Beta-actin | Common loading control in IgM expression studies. |
How Is hexameric IgM immunoglobulin complex Regulated?
The production and assembly of hexameric IgM are regulated at multiple levels. Transcription of the IGHM gene is controlled by transcription factors such as Pax5 and Blimp-1 during plasma cell differentiation. The J chain expression is also regulated and is essential for polymerization. Post-translational regulation includes glycosylation and disulfide bond formation, which affect secretion and function. Additionally, the interaction of hexameric IgM with FcμR regulates its clearance and immune modulatory functions. Complement regulatory proteins also modulate the effector functions of hexameric IgM.
hexameric IgM immunoglobulin complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IGHM | Hyper-IgM syndrome, agammaglobulinemia | Knockout mice or CRISPR KO in plasma cell lines |
| JCHAIN | Impaired IgM polymerization, immunodeficiency | Jchain knockout mice or CRISPR KO in B cells |
| C1QA | SLE, complement deficiency | C1qa knockout mice, CRISPR point mutations |
| FCAMR | Immune dysregulation, autoimmunity | Fcamr knockout mice, CRISPR KO in B cell lines |
| CD5L | Metabolic and immune disorders | Cd5l knockout mice, overexpression models |
Autoimmune Diseases
Hexameric IgM is implicated in autoimmune diseases such as systemic lupus erythematosus (SLE). Anti-C1q autoantibodies, often of the IgM class, can bind to C1q and enhance phagocytosis but not complement activation, contributing to disease pathology. The presence of hexameric IgM in immune complexes can exacerbate inflammation and tissue damage. Understanding the role of hexameric IgM in autoimmunity may lead to new therapeutic strategies.
Cancer Immunotherapy
Engineered hexameric IgM molecules are being developed as cancer therapeutics. For example, IGM-7354, an immunocytokine with IL15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1-positive tumor cells. The hexameric structure provides high avidity and potent complement activation, making it an attractive scaffold for antibody-based cancer therapy.
Infectious Diseases
Hexameric IgM plays a crucial role in the early defense against pathogens. Its high avidity and potent complement activation enable efficient neutralization and clearance of bacteria and viruses. Studying hexameric IgM can inform vaccine design and the development of passive immunotherapies.
Primary Immunodeficiencies
Defects in IgM assembly or secretion can lead to primary immunodeficiencies such as hyper-IgM syndrome. Mutations in genes involved in class-switch recombination or the J chain can result in reduced levels of hexameric IgM and increased susceptibility to infections.
From hexameric IgM immunoglobulin complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of J chain in hexameric IgM assembly? | Jchain knockout mice or CRISPR KO in IgM-producing cell lines |
| How does N-glycosylation affect hexameric IgM function? | Point mutations at specific N-glycosylation sites using CRISPR |
| What is the effect of FcμR on hexameric IgM clearance? | Fcamr knockout mice or tagged knock-in of FcμR |
| Can engineered hexameric IgM enhance tumor killing? | Knock-in of IL15-PD-L1 fusion into IgM locus in hybridoma cells |
| How does C1q binding differ between pentameric and hexameric IgM? | Overexpression of recombinant IgM variants in HEK293 cells |
| What is the impact of CD5L on IgM stability? | Cd5l knockout and overexpression in hepatoma cell lines |
How to Study the hexameric IgM immunoglobulin complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Recombinant expression | Production of hexameric IgM | Structure-function studies, therapeutic development |
| Biolayer interferometry | Binding kinetics (kon, koff, KD) | C1q binding to IgM oligomers |
| Mass spectrometry | N-glycosylation sites and glycan structures | Characterization of IgM post-translational modifications |
| CRISPR-Cas9 knockout | Gene function | Dissecting roles of JCHAIN, FCAMR, etc. |
| Flow cytometry | Cell surface binding and internalization | FcμR-mediated uptake of IgM |
| ELISA | Quantification of IgM in serum | Diagnosis of immunodeficiency |
| Western blot | Protein expression and assembly | Analysis of IgM subunits |
| Immunoprecipitation | Protein-protein interactions | Identification of IgM-associated proteins like CD5L |
Recombinant Expression and Purification
Recombinant hexameric IgM can be expressed in mammalian cells such as HEK293 or CHO cells by co-transfecting plasmids encoding IgM heavy and light chains and the J chain. Purification is typically achieved using affinity chromatography with anti-IgM antibodies or protein L. This method allows for the production of sufficient quantities for structural and functional studies.
Biophysical Characterization
Biophysical techniques such as biolayer interferometry (BLI) and surface plasmon resonance (SPR) are used to measure the binding kinetics of hexameric IgM to C1q and other ligands. These methods provide quantitative data on affinity and avidity, which are critical for understanding the effector functions of hexameric IgM.
Glycosylation Analysis
Site-specific N-glycosylation of hexameric IgM can be analyzed using mass spectrometry-based approaches such as LC-MS/MS after enzymatic digestion. This reveals the glycan structures at each N-glycosylation site and their impact on IgM function.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 is used to generate knockout, point mutation, and knock-in models to study the genes involved in hexameric IgM assembly and function. For example, knocking out JCHAIN or FCAMR in B cell lines can elucidate their roles in IgM polymerization and clearance.
How CRISPR Can Be Used to Study GO:0071757 hexameric IgM immunoglobulin complex
Knockout
CRISPR-Cas9 knockout of genes such as JCHAIN, IGHM, or FCAMR in relevant cell lines (e.g., B cell lines, hybridomas) can abolish hexameric IgM assembly or function. These models are invaluable for studying the specific roles of these genes in IgM biology.
Point Mutation
Point mutations can be introduced into the IGHM gene to alter specific amino acids involved in polymerization or glycosylation. For example, mutating cysteine residues that form disulfide bonds can prevent hexamer formation, allowing detailed structure-function analysis.
Knock-in
Knock-in of tagged versions of IgM heavy chain (e.g., FLAG or HA tags) or fusion proteins (e.g., IL15-PD-L1) enables tracking and functional studies. This approach is used to generate engineered hexameric IgM for therapeutic applications.
Overexpression
Overexpression of wild-type or mutant IgM subunits and J chain in cell lines can drive the production of hexameric IgM for biochemical and structural studies. This is particularly useful when natural sources are limited.
How EDITGENE Supports hexameric IgM immunoglobulin complex Research
Researchers studying hexameric IgM immunoglobulin complex-related genes often need to determine whether a candidate gene is causally involved in its assembly, secretion, or function. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for hexameric IgM immunoglobulin complex research.
Frequently Asked Questions About hexameric IgM immunoglobulin complex
What is GO:0071757?
GO:0071757 is the Gene Ontology term for the hexameric IgM immunoglobulin complex, a circulating form of IgM consisting of six IgM core units and one J chain polypeptide.
What is hexameric IgM?
Hexameric IgM is a polymeric form of immunoglobulin M composed of six IgM monomers linked by a single J chain, found in circulation and involved in complement activation.
What genes are involved in hexameric IgM immunoglobulin complex?
Key genes include IGHM (μ heavy chain), JCHAIN (J chain), FCAMR (FcμR receptor), and complement genes C1QA, C1QB, C1QC.
How is hexameric IgM different from pentameric IgM?
Hexameric IgM contains six IgM units and one J chain, while pentameric IgM contains five units and one J chain; they differ in complement activation and receptor binding.
What is the function of hexameric IgM?
Hexameric IgM activates the classical complement pathway, neutralizes pathogens, and forms immune complexes for clearance.
What diseases are associated with hexameric IgM?
Hexameric IgM is implicated in autoimmune diseases like SLE, hyper-IgM syndrome, and is being explored in cancer immunotherapy.
How can I study hexameric IgM using CRISPR?
CRISPR can be used to knockout, mutate, or knock-in genes such as JCHAIN or IGHM in cell lines to study their roles in hexameric IgM assembly and function.
What methods are used to analyze hexameric IgM?
Methods include recombinant expression, biolayer interferometry, mass spectrometry for glycosylation, and ELISA.
What is the role of the J chain in hexameric IgM?
The J chain is essential for polymerization and secretion of hexameric IgM; without it, IgM cannot form hexamers.
How does hexameric IgM activate complement?
Hexameric IgM binds to C1q, triggering the classical complement cascade, leading to opsonization and lysis of pathogens.
Conclusion
The hexameric IgM immunoglobulin complex (GO:0071757) is a critical component of the humoral immune system, with unique structural and functional properties that distinguish it from pentameric IgM. Its ability to potently activate complement and interact with FcμR makes it a key player in immune defense and autoimmune pathology. Advances in recombinant expression, biophysical characterization, and CRISPR-based genome editing are providing new insights into its assembly and function. EDITGENE's comprehensive CRISPR services can support researchers in dissecting the genetic basis of hexameric IgM biology and developing novel therapeutics.
References
- 1. Li Y et al.. 2023. Immunoglobulin M perception by FcμR.. Nature 615(7954):907-912 PMID: 36949194
- 2. Oskam N et al.. 2023. CD5L is a canonical component of circulatory IgM.. Proc Natl Acad Sci U S A 120(50):e2311265120 PMID: 38055740
- 3. Moh ES et al.. 2016. Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM.. J Am Soc Mass Spectrom 27(7):1143-55 PMID: 27038031
- 4. Desbois M et al.. 2025. IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells.. Cancer Immunol Res 13(8):1172-1189 PMID: 40402523
- 5. Hasegawa H et al.. 2024. Understanding the biosynthesis of human IgM SAM-6 through a combinatorial expression of mutant subunits that affect product assembly and secretion.. PLoS One 19(6):e0291568 PMID: 38848420
- 6. Dijkstra DJ et al.. 2023. Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation.. Proc Natl Acad Sci U S A 120(50):e2310666120 PMID: 38048459
- 7. Reid KB. 1989. Chemistry and molecular genetics of C1q.. Behring Inst Mitt PMID: 2679537
- 8. Chouquet A et al.. 2022. Biophysical Characterization of the Oligomeric States of Recombinant Immunoglobulins Type-M and Their C1q-Binding Kinetics by Biolayer Interferometry.. Front Bioeng Biotechnol 10:816275 PMID: 35685087
